Remember when Pfizer was everywhere? From nightly news to every vaccine card in your wallet, it was the face of the pandemic ...

For U.S. Big Pharma companies, vaccines have largely been an afterthought. But by 2030, they could be a quarter of Pfizer’s revenue.

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.

Pfizer achieved 10% year-over-year Q2 2025 revenue growth to $14.7 billion. Click here to find out why PFE stock is a Buy.

Johnson & Johnson and Roche are reportedly in discussions with Shanghai Henlius Biotech, a unit of Fosun Pharma, over the ...